OncoMed Pharmaceuticals, Inc. (OMED) CEO Testifies On Behalf Of Biotechnology Industry Organization (BIO) At Congressional Hearing On FDA Drug Development And Manufacturing Challenges
12/13/2013 9:27:58 AM
WASHINGTON--(BUSINESS WIRE)--Today, the House Committee on Oversight & Government Reform, Subcommittee on Energy Policy, Health Care & Entitlements held a hearing entitled, “FDA Check-Up: Drug Development and Manufacturing Challenges.” Paul Hastings, Chairman and Chief Executive Officer of California-based OncoMed Pharmaceuticals and Chairman of BIO’s Emerging Companies Section Governing Board, presented testimony at the hearing emphasizing the positive indicators that demonstrate the biopharma industry is rebounding, but significant financial and regulatory challenges remain.
Help employers find you! Check out all the jobs and post your resume.